Insmed reported $543.51M in Loan Capital for its fiscal quarter ending in June of 2026.





Loan Capital Change Date
BioMarin Pharmaceutical USD 3.53B 2.1B Jun/2026
Cytokinetics USD 248.2M 993K Jun/2026
DBV Technologies USD 0 0 Mar/2025
Gilead Sciences USD 20.86B 1.27B Mar/2026
Heron Therapeutics USD 140.64M 975K Dec/2025
Insmed USD 543.51M 1.3M Jun/2026
Novartis USD 37.45B 7.86B Mar/2026
Regeneron Pharmaceuticals USD 1.99B 400K Jun/2026
Sarepta Therapeutics USD 847.62M 9.46M Jun/2026
Ultragenyx Pharmaceutical USD 1.13B 19M Mar/2026
Vertex Pharmaceuticals USD 106.7M 4.7M Dec/2025